Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis

OBJECTIVES: To examine whether treatment with anti‐tumour necrosis factor (TNF) α prevents loss of bone mineral density (BMD) at the spine and hip (generalised) and in the hands (local) of patients with rheumatoid arthritis, and to study the changes in markers of bone metabolism, including receptor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Vis, M, Havaardsholm, E A, Haugeberg, G, Uhlig, T, Voskuyl, A E, van de Stadt, R J, Dijkmans, B A C, Woolf, A D, Kvien, T K, Lems, W F
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2006
Assuntos:
Extended Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798341/
https://ncbi.nlm.nih.gov/pubmed/16606653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2005.044198
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados